Michael Babula
Payments from drug & device makers
Across 132 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$525
- GSK$453
- AbbVie$256
- Gilead$215
- Boston Scientific$202
- Pfizer$150
- plus $996 from 17 others
What the payments were for
- Food & beverage$2,796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $525 |
| GSK | 22 | $453 |
| AbbVie | 12 | $256 |
| Gilead | 11 | $215 |
| Boston Scientific | 3 | $202 |
| Pfizer | 9 | $150 |
| Lilly USA, LLC | 9 | $145 |
| AstraZeneca | 8 | $137 |
| Bayer | 6 | $113 |
| Shield Therapeutics Inc | 6 | $113 |
| Amgen | 5 | $85 |
| Exact Sciences | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Merck | 2 | $38 |
| Novartis | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Vertex | 1 | $23 |
| Electromed, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $14 |
How this compares
$2,796 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 81 | $52,716 |
| JardianceEmpagliflozin | 47 | $38,711 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $35,684 |
| EliquisApixaban | 33 | $24,535 |
| XareltoRivaroxaban | 26 | $22,191 |
| OzempicSemaglutide | 18 | $18,868 |
| KerendiaFinerenone | 18 | $14,726 |
| LinzessLinaclotide | 26 | $13,392 |
| JanuviaSitagliptin Phosphate | 19 | $11,758 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 147 | $3,793 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,148 |
| Gabapentin | 220 | $2,162 |
| Alendronate Sodium | 11 | $1,958 |
| Omeprazole | 141 | $1,805 |
| Famotidine | 65 | $1,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $137 | $52,71681 claims |
| Boehringer IngelheimJardiance | $34 | $38,71147 claims |
| GSKTrelegy Ellipta | $453 | $35,68448 claims |
| PfizerEliquis | $150 | $24,53533 claims |
| BayerKerendia | $113 | $14,72618 claims |
| AbbVieLinzess | $256 | $13,39226 claims |
| MerckJanuvia | $38 | $11,75819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.
Other family in Utica
- Jenna PawloskiUtica$62K
- Nicolette HaleyUtica$19K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.